BR112014003167A2 - pharmaceutical composition consisting of a drug containing at least one toxicophor function and n-acetyl-1-cysteine - Google Patents

pharmaceutical composition consisting of a drug containing at least one toxicophor function and n-acetyl-1-cysteine

Info

Publication number
BR112014003167A2
BR112014003167A2 BR112014003167A BR112014003167A BR112014003167A2 BR 112014003167 A2 BR112014003167 A2 BR 112014003167A2 BR 112014003167 A BR112014003167 A BR 112014003167A BR 112014003167 A BR112014003167 A BR 112014003167A BR 112014003167 A2 BR112014003167 A2 BR 112014003167A2
Authority
BR
Brazil
Prior art keywords
toxicophor
cysteine
acetyl
function
pharmaceutical composition
Prior art date
Application number
BR112014003167A
Other languages
Portuguese (pt)
Inventor
Assndri Alessandro
Van Gulik Frederick
Original Assignee
Cross Sa
Eurodrug Laboratories B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cross Sa, Eurodrug Laboratories B V filed Critical Cross Sa
Publication of BR112014003167A2 publication Critical patent/BR112014003167A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014003167A 2011-08-11 2011-08-11 pharmaceutical composition consisting of a drug containing at least one toxicophor function and n-acetyl-1-cysteine BR112014003167A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/063829 WO2013020600A1 (en) 2011-08-11 2011-08-11 Pharmaceutical composition comprising a drug containing at least one toxicophore function and n-acetyl-l-cysteine

Publications (1)

Publication Number Publication Date
BR112014003167A2 true BR112014003167A2 (en) 2017-03-01

Family

ID=44510961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003167A BR112014003167A2 (en) 2011-08-11 2011-08-11 pharmaceutical composition consisting of a drug containing at least one toxicophor function and n-acetyl-1-cysteine

Country Status (5)

Country Link
EP (1) EP2741742A1 (en)
KR (1) KR20140147799A (en)
BR (1) BR112014003167A2 (en)
MX (1) MX2014001679A (en)
WO (1) WO2013020600A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020129509A1 (en) * 2018-12-21 2020-06-25 富士フイルム株式会社 Phototoxicity or photoallergy measurement method and reagent for use in said measurement method
WO2023075826A1 (en) * 2021-10-28 2023-05-04 The Texas A&M University System Compositions of stable metformin and similar drug products with control on nitroso impurities

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971743B1 (en) * 1997-04-18 2006-07-12 Fritz Stanislaus Stabilized medicaments containing cysteinyl derivatives
DK1767219T3 (en) * 2004-03-10 2010-05-10 Shimoda Biotech Pty Ltd Stable injectable diclofenac compositions

Also Published As

Publication number Publication date
MX2014001679A (en) 2014-10-15
WO2013020600A1 (en) 2013-02-14
EP2741742A1 (en) 2014-06-18
KR20140147799A (en) 2014-12-30

Similar Documents

Publication Publication Date Title
DK3181128T3 (en) NILOTINIB PHARMACEUTICAL COMPOSITION
BRPI1012246A2 (en) pharmaceutical composition containing a drug and sirna
CR20130406A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HUMAN ANTIBODIES AGAINST PCSK9
BR112015004936A2 (en) coated pharmaceutical composition containing regorafenib
DK2694038T3 (en) PHARMACEUTICAL COMPOSITION
BR112013008882A2 (en) dose setting mechanism for a drug delivery device and method of administering at least one dose
DK2785352T3 (en) STABLE INJECTABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND ALFAXALON
BR112014013760A2 (en) compound, pharmaceutical composition and use of a compound
BR112015000420A2 (en) compound, pharmaceutical composition, and use of a compound
DK3246018T3 (en) PHARMACEUTICAL COMPOSITION
BR112014005669A2 (en) compound, pharmaceutical composition and use of a compound
BR112013014644A2 (en) pharmaceutical composition and complex
BR112014003567A2 (en) compound use of a compound and pharmaceutical composition
DK3603704T3 (en) ADMINISTRATION OF MEDICATION
EE201300005A (en) Pharmaceutical composition
BR112014020992A2 (en) Compound, use of compound in the manufacture of a medicine and pharmaceutical composition
BR112014014536A2 (en) an inhaler comprising a tiotropium-containing composition
CU24163B1 (en) TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
BR112014009889A2 (en) disubstituted compounds, compounds and pharmaceutical composition
DK2815752T3 (en) ORAL PHARMACEUTICAL COMPOSITION
DK2542224T3 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANETEXILATE
BR112014013178A2 (en) compound, pharmaceutical composition and use of a compound
CO7010828A2 (en) Pharmaceutical preparation comprising substituted ßcyclodextrin
BR112015002360A2 (en) composition comprising a pesticide mixture of terpene and a fungicide
BR112013033861A2 (en) compound, use of a compound, pharmaceutical composition, cosmetic composition and cosmetic use of a composition

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)